IL‐6 is a cytokine secreted by cancer and stromal cells, including CAFs and tumor‐associated macrophages,[56] and elevated expression has been linked to tumor progression and poor survival in pancreatic cancer patients.[56] To assess the potential of ADH‐503 in altering cytokine secretion, we next analyzed the secretory profile in our TME model upon treatment and found significantly reduced IL‐6 levels, which were no longer detectable in multicellular MIAPaCa‐2 cultures in response to ADH‐503/αPD‐1/GEM/PTX treatment. This evidence concerns the gene IL6 and pancreatic neoplasm.